Skip to main content

Absci Corp

corporate_fare Company Profile

Absci Corp

ABSI·NASDAQ·Industrial Applications And Services·CIK 0001672688

Absci Corp is a clinical-stage biopharmaceutical company that uses an AI-native approach to develop antibody therapeutics. The company's integrated drug creation platform combines Origin-1, a generative design model, with rapid validation using its lab-in-the-loop system. Absci focuses on underexplored biological mechanisms where there is a high unmet medical need and low competition. The company has advanced its first two programs from AI design to an Investigational New Drug (IND) application (or foreign equivalent) in approximately two years, with a total investment of about $15 million per program. This compares to an industry average of 4-6 years at a cost greater than $50 million. Absci's lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life for patient-friendly dosing. ABS-201 is being developed for two indications: androgenetic alopecia (AGA) and endometriosis. Androgenetic alopecia, also known as pattern hair loss (PHL), affects approximately 80 million people in the United States. ABS-201 is currently being evaluated in the HEADLINE™ Phase 1/2a clinical trial (NCT07317544) for AGA. The company has dosed the first three single ascending dose cohorts with a favorable safety profile to date, and interim proof-of-concept data, including exploratory efficacy endpoints, are expected in the second half of 2026. For endometriosis, a chronic condition estimated to affect approximately 10% of women of reproductive age worldwide, Absci plans to initiate a Phase 2 clinical trial of ABS-201.

Absci Corp (NASDAQ:ABSI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for ABSI at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Absci Details Significant Clinical Progress for Lead Asset ABS-201 at J.P. Morgan Conference

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.8M
Net Income
-$115.18M
Diluted EPS
-$0.84
Op. Cash Flow
-$92.92M
Free Cash Flow
-$94.03M
Operating Income
-$120.32M
Cash & Equivalents
$20.02M
Debt / Equity
0.00×
Net Margin
-41.14×
Shares Outstanding
136.78M sh
Source: 10-K · filed 2026-03-24 · accession 0001672688-26-000068
$7.61 +1.33% today
52-week range · as of 2026-11-12 $2.24 – $12.54
Market cap
$1.3B
Volume
4.7M (1.1× avg)
3-mo avg 4.3M
Live data · 2026-11-22 07:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABSI - Filings & News (Page 2)

ABSI
Jan 14, 2026, 5:27 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.41
Real-time Price: $7.61 info
Change: +$4.20 (+123%) info
Market Cap: $1.297B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets